ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Financial Review

ArriVent BioPharma (NASDAQ:AVBP) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares ArriVent BioPharma and Sunshine Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-59.58%	-55.66%
Sunshine Biopharma	-16.06%	-24.96%	-19.46%

Risk & Volatility

ArriVent BioPharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Insider and Institutional Ownership

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 18.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for ArriVent BioPharma and Sunshine Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	2	0	7	1	2.70
Sunshine Biopharma	1	0	1	0	2.00

ArriVent BioPharma presently has a consensus target price of $39.38, suggesting a potential upside of 59.48%. Sunshine Biopharma has a consensus target price of $7.00, suggesting a potential upside of 389.51%. Given Sunshine Biopharma’s higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than ArriVent BioPharma.

Valuation and Earnings

This table compares ArriVent BioPharma and Sunshine Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$80.49 million	($4.24)	-5.82
Sunshine Biopharma	$34.87 million	0.20	-$5.13 million	($1.02)	-1.40

Sunshine Biopharma has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Sunshine Biopharma beats ArriVent BioPharma on 8 of the 13 factors compared between the two stocks.

About ArriVent BioPharma

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

About Sunshine Biopharma

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.